Q1 EPS Estimate for Mirum Pharmaceuticals Lifted by Analyst

Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) – HC Wainwright raised their Q1 2027 earnings estimates for shares of Mirum Pharmaceuticals in a research report issued to clients and investors on Monday, September 28th. HC Wainwright analyst S. Ramakanth now forecasts that the company will earn $0.09 per share for the quarter, up from their prior estimate of $0.08. HC Wainwright has a “Buy” rating and a $195.00 price objective on the stock. The consensus estimate for Mirum Pharmaceuticals’ current full-year earnings is ($1.31) per share. HC Wainwright also issued estimates for Mirum Pharmaceuticals’ Q2 2027 earnings at $0.18 EPS, Q4 2027 earnings at $0.80 EPS and FY2027 earnings at $1.42 EPS.

MIRM has been the topic of several other research reports. TD Cowen cut their target price on Mirum Pharmaceuticals from $145.00 to $140.00 and set a “buy” rating on the stock in a research report on Thursday, August 6th. Wall Street Zen lowered shares of Mirum Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Sunday, September 6th. Royal Bank Of Canada cut their target price on shares of Mirum Pharmaceuticals from $148.00 to $135.00 and set an “outperform” rating on the stock in a research note on Thursday, August 6th. UBS Group set a $137.00 price target on shares of Mirum Pharmaceuticals in a research note on Thursday, August 27th. Finally, Robert W. Baird increased their price objective on shares of Mirum Pharmaceuticals from $123.00 to $130.00 and gave the stock an “outperform” rating in a research report on Tuesday. One research analyst has rated the stock with a Strong Buy rating, thirteen have given a Buy rating and one has given a Sell rating to the stock. Based on data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $142.56.

Mirum Pharmaceuticals Price Performance

MIRM stock opened at $85.48 on Tuesday. The company has a quick ratio of 2.74, a current ratio of 2.86 and a debt-to-equity ratio of 1.28. The company’s fifty day simple moving average is $99.16 and its 200 day simple moving average is $101.42. Mirum Pharmaceuticals has a 12-month low of $63.23 and a 12-month high of $130.00. The firm has a market cap of $5.55 billion, a price-to-earnings ratio of -5.87 and a beta of 0.49.

Mirum Pharmaceuticals (NASDAQ:MIRM) last issued its quarterly earnings results on Wednesday, August 5th. The company reported ($1.06) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.74) by ($0.32). Mirum Pharmaceuticals had a negative return on equity of 36.28% and a negative net margin of 139.18%.The firm had revenue of $176.24 million during the quarter, compared to analyst estimates of $166.33 million. During the same quarter last year, the firm posted ($0.12) EPS. The firm’s revenue for the quarter was up 37.9% on a year-over-year basis.

Insider Transactions at Mirum Pharmaceuticals

In other news, SVP Jolanda Howe sold 658 shares of the company’s stock in a transaction on Wednesday, September 2nd. The shares were sold at an average price of $100.00, for a total value of $65,800.00. Following the completion of the sale, the senior vice president owned 616 shares in the company, valued at $61,600. This represents a 51.65% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Christopher Peetz sold 30,000 shares of the firm’s stock in a transaction dated Tuesday, September 1st. The shares were sold at an average price of $98.68, for a total transaction of $2,960,400.00. Following the transaction, the chief executive officer directly owned 194,440 shares in the company, valued at $19,187,339.20. The trade was a 13.37% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold a total of 123,499 shares of company stock worth $12,854,484 in the last quarter. 8.32% of the stock is currently owned by corporate insiders.

Institutional Trading of Mirum Pharmaceuticals

A number of institutional investors and hedge funds have recently modified their holdings of MIRM. ABS Investment Management LLC bought a new stake in Mirum Pharmaceuticals during the second quarter worth $245,847,000. Integrated Wealth Concepts LLC bought a new position in Mirum Pharmaceuticals in the 2nd quarter valued at $27,000. Quantbot Technologies LP purchased a new stake in shares of Mirum Pharmaceuticals during the 2nd quarter valued at $44,000. Eurizon Capital SGR S.p.A. purchased a new stake in shares of Mirum Pharmaceuticals during the 4th quarter valued at $32,000. Finally, State of Wyoming bought a new stake in shares of Mirum Pharmaceuticals during the 2nd quarter worth $52,000.

Mirum Pharmaceuticals News Summary

Here are the key news stories impacting Mirum Pharmaceuticals this week:

• Positive Sentiment: Positive Phase 3 data for brelovitug: Mirum said brelovitug met the primary endpoint in the AZURE-1 study for chronic hepatitis delta virus, reporting strong virologic response and alanine aminotransferase normalization rates. The result strengthens the company’s pipeline and potential future growth. Mirum’s Brelovitug Meets Goal in Phase III AZURE-1 Study in HDV
• Positive Sentiment: FDA approval for Atebrioz: Mirum reportedly received FDA approval for Atebrioz, adding a regulatory milestone that could support commercial revenue and broaden the company’s product portfolio. Mirum wins FDA approval for Atebrioz
• Positive Sentiment: HC Wainwright raised its long-term earnings outlook and maintained a Buy rating with a $195 price target. Its EPS forecasts increased for fiscal 2027 to $1.42, fiscal 2028 to $5.38, fiscal 2029 to $7.21, and fiscal 2030 to $10.03. Baird also raised its target to $130 and maintained an Outperform rating. Mirum Pharmaceuticals Stock Price Expected to Rise, HC Wainwright Analyst Says
• Neutral Sentiment: Analyst estimates remain mixed in the near term: HC Wainwright raised its Q3 2026 EPS forecast from a loss of $0.31 to positive $0.07 and slightly improved its Q4 2026 estimate, but reduced its Q3 2027 forecast to $0.35 from $0.40. The firm still expects Mirum to report a full-year loss of $1.31.
• Neutral Sentiment: An investor survey comparing Mirum with Sarepta Therapeutics provides additional market commentary but does not represent a material change to Mirum’s fundamentals. Mirum Pharmaceuticals and Sarepta Therapeutics Head-To-Head Survey

Mirum Pharmaceuticals Company Profile

Mirum Pharmaceuticals, Inc is a biopharmaceutical company focused on developing and commercializing medicines for rare diseases of the liver and gastrointestinal system. The company’s work centers on conditions involving impaired bile acid transport and cholestasis, which can cause serious liver damage and debilitating symptoms such as itching.

Mirum’s primary commercial product is Livmarli (maralixibat), an oral ileal bile acid transporter inhibitor. In the United States, Livmarli is approved to treat cholestatic pruritus associated with Alagille syndrome and progressive familial intrahepatic cholestasis in eligible pediatric patients.